ArticleScientific reports2022

Chronic treatment with serelaxin mitigates adverse remodeling in a murine model of ischemic heart failure and modulates bioactive sphingolipid signaling.

Teja Devarakonda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.